Ajanta Pharmaceuticals (АЈАРНА)



CMP: ₹ 1512

Target: ₹ 181<u>0 (20%)</u>

Target Period: 12 months

July 31, 2020

Steady revenue growth, strong margins...

Q1FY21 revenues grew 9.2% YoY to ₹ 668 crore mainly due to 46.1% growth in the US business to ₹ 149 crore and 27.8% growth in Asia revenues to ₹ 161 crore. Domestic revenues de-grew 10.3% YoY to ₹ 174 crore. EBITDA margins improved 589 bps to 33.4% mainly due to lower other expenditure. Subsequently, EBITDA grew 32.6% YoY to ₹ 223 crore. Net profit grew 28.9% YoY to ₹ 148 crore. Delta vis-à-vis EBITDA was mainly due to higher tax rate and depreciation partially offset by higher other income.

Domestic formulations - Focus on new launches, few therapies

Domestic formulations comprise 30% of FY20 revenues. The main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in dermatology segment due to increased competition in existing products and slow offtake in new launches are some near term challenges. We expect domestic formulations to grow at ~11% CAGR in FY20-22E to ₹ 946 crore to be driven by existing products & new launches.

Exports traction from EMs; US generics shaping up

Ajanta derives export revenues (70% of FY20 revenues) from emerging markets like Africa (Franco Africa), Asia and from US. In emerging markets, as opposed to common practice of forging alliances with regional pharma players, its front-end marketing team interacts directly with doctors. The US foray is also getting momentum. Despite volatility in African tender business, overall export formulations CAGR has been a steady 11% in FY16-20. We expect export formulations to grow at 10.4% CAGR in FY20-22E to ₹ 2183 crore driven by Asia, African branded business, strong growth in US.

Valuation & Outlook

Source: ICICI Direct Research

Despite a dent in domestic sales in Q1FY21 due to Covid-19, overall revenue growth remained steady on the back of strong growth in US and branded export formulations. Additionally, Ajanta posted a strong margin performance in the quarter, led by lower travel & promotional spends along with change in product mix. While the management expects subdued domestic growth in FY21 due to Covid-19, it expects high single digit growth for branded business in Asia and Africa (India, Asia, Africa- ~70% of sales) along with ~10% growth for the US. On margins front, change in product mix (increase US revenues) notwithstanding, the management expects ~200-250 bps improvement over FY20, going ahead, with improving operating leverage and moderating capex. Overall, calculated focus, healthy margins, return profile and lighter balance sheet are some key differentiators for Ajanta. The company remains a play on global branded generics space. We arrive at our target price of ₹ 1810 based on 25x FY22E EPS of ~₹ 72.5.



Particulars	
Particular	Amount
Market Capitalisation	₹13194 crore
Debt (FY20)	₹44 crore
Cash (FY 20)	₹205 crore
EV	₹13032 crore
52 week H/L	1578/882
Equity capital	₹17.5 crore
Face value	₹2
Kov Highlights	

Key Highlights

- Q1FY21 revenues were in-line with Idirect estimates, whereas profitability was better than our expectations on account of lower travel and promotional spends.
- Guided for high single digit growth in Asian and African branded business and 10% growth for the US in FY21
- Maintain BUY

Research Analyst

Siddhant Khandekar siddhant.khandekar@icicisecurities.com

Mitesh Shah, CFA mitesh.sha@icicisecurities.com

Sudarshan Agarwal sudarshan.agarwal@icicisecurities.com

Key Financial Summary					
₹Crore	FY19	FY20	FY21E	FY22E	CAGR FY20-22 (%)
Revenues	2053.0	2587.9	2768.2	3191.5	11.1
EBITDA	555.8	683.3	820.9	957.4	18.4
EBITDA margins (%)	27.1	26.4	29.7	30.0	
Net Profit	384.6	467.7	531.9	640.2	17.0
EPS(₹)	43.5	53.4	60.2	72.5	
PE (x)	34.7	28.6	25.1	20.9	
M.Cap/Revenues (x)	6.5	5.2	4.8	4.2	
EV to EBITDA (x)	23.8	19.2	15.8	13.3	
RoCE (%)	21.8	24.7	23.4	24.3	
ROE (%)	17.1	18.1	17.7	18.4	

ICICI Direct Researc

	Q1FY21	Q1FY21E	Q1FY20	Q4FY20	YoY (%)	QoQ (%)	Comments
Revenue	668.2	662.3	611.9	682.0	9.2	-2.0	YoY growth mainly due to strong growth in US and branded export formulations partially offset by decline in domestic branded business
Raw Material Expenses	153.1	172.2	142.5	177.6	7.4	-13.8	A 38 bps YoY improvement in gross margins and beat vis-à- vis l-direct estimates due to change in product mix
Employee Expenses	135.8	132.5	118.3	129.5	14.8	4.9	
Other Expenditure	156.1	185.4	182.7	223.5	-14.6	-30.2	YoY, QoQ decline due to lower travel and promotional spends
Total Operating Expenditure	445.0	490.1	443.6	530.6	0.3	-16.1	
EBITDA	223.2	172.2	168.4	151.3	32.6	47.5	
EBITDA (%)	33.4	26.0	27.5	22.2	589 bps	1121 bps	YoY improvement and beat vis-à-vis l-direct estimates mainly due to significantly lower other expenditure
Interest	1.6	3.0	1.8	3.6	-8.9	-55.0	
Depreciation	28.0	27.7	22.8	26.0	23.0	7.6	
Other income	13.1	5.3	7.6	56.7	71.7	-76.9	
PBT before EO	206.7	146.8	151.5	178.4	36.5	15.9	
Less: Exceptional Items	0.0	0.0	0.0	2.5	0.0	0.0	
PBT	206.7	146.8	151.5	175.9	36.5	17.5	
Tax	58.9	41.1	36.8	46.7	60.0	26.2	
MI & Share of loss/ (gain) asso.	0.0	0.0	0.0	0.0	0.0	0.0	
Adj. Net Profit	147.8	105.7	114.6	131.7	28.9	12.2	Delta vis-à-vis EBITDA mainly due to higher tax rate and depreciation partially offset by higher other income
Key Metrics							
India	174.0	195.7	194.0	177.0	-10.3	-1.7	YoY de-growth due to decline in ophthalmic and dermatology segment partially offset by growth in cardiac
Africa - Branded	108.0	92.0	92.0	95.0	17.4	13.7	Strong YoY growth mainly due to Covid-related stocking
Africa - Tender	62.0	64.8	81.0	43.0	-23.5	44.2	YoY decline mainly due to higher base
Asia	161.0	138.6	126.0	209.0	27.8	-23.0	Strong YoY growth was mainly due to lower base
US	149.0	155.9	102.0	143.0	46.1	4.2	YoY robust growth mainly due to increased market share and volume gains in key products
Total Export	483.0	453.7	403.2	491.0	19.8	-1.6	

Exhibit 2: Change in Estimates

		FY21E			FY22E	
(₹ Crore)	Old	New	% Change	Old	New	% Change
Revenue	2,861.4	2,768.2	-3.3	3,286.4	3,191.5	-2.9
EBITDA	788.3	820.9	4.1	953.1	957.4	0.5
EBITDA Margin (%)	27.5	29.7	215 bps	29.0	30.0	100 bps
PAT	494.9	531.9	7.5	637.0	640.2	0.5
EPS (₹)	56.0	60.2	7.5	72.1	72.5	0.5

Source: ICICI Direct Research

Exhibit 3: Chan	ge in Estimate	s					
		(Current		Earlier		Comments
(₹ crore)	FY19	FY20	FY21E	FY22E	FY21E	FY22E	
Domestic	690.0	769.0	788.2	945.8	853.3	965.2	Changed as per management guidance and due to Covid-19 impact
Africa	502.0	594.0	599.2	649.6	574.1	634.0	Changed as per management guidance
Asia	528.0	674.0	726.2	816.5	723.3	838.3	
US	283.0	515.0	591.9	708.2	647.0	776.4	Changed as per management guidance

Source: ICICI Direct Research

Exhibit 4: Trends in c	quarter	ly finan	cials												
(₹crore)	.1FY18	2FY18	3FY 18	4FY18	1FY19	2FY19	3FY19	4FY19	1FY 20	2FY 20	3FY 20	4FY 20	1FY21	YoY (%)	Q o Q (%)
Total Operating Income	473.1	540.4	587.1	530.3	511.0	544.1	485.1	515.2	611.9	642.8	651.2	682.0	668.2	9.2	-2.0
Raw Material Expenses	93.6	109.0	110.0	93.8	84.1	95.9	97.9	105.5	142.5	166.5	169.1	177.6	153.1	7.4	-13.8
% of Revenue	19.8	20.2	18.7	17.7	16.5	17.6	20.2	20.5	23.3	25.9	26.0	26.0	22.9	-38 bps	-313 bps
Gross Profit	379.5	431.4	477.1	436.6	426.9	448.2	387.2	409.6	469.4	476.3	482.1	504.4	515.1	9.7	2.1
GPM (%)	80.2	79.8	81.3	82.3	83.5	82.4	79.8	79.5	76.7	74.1	74.0	74.0	77.1	38 bps	313 bps
Employee Expenses	86.7	89.4	95.2	105.2	104.8	105.8	112.8	107.4	118.3	117.4	120.4	129.5	135.8	14.8	4.9
% of Revenue	18.3	16.5	16.2	19.8	20.5	19.4	23.2	20.8	19.3	18.3	18.5	19.0	20.3	99 bps	134 bps
O ther Expenditure	162.1	158.2	184.3	191.9	164.6	176.2	167.1	175.2	182.7	181.2	175.8	223.5	156.1	-14.6	-30.2
% of Revenue	34.3	29.3	31.4	36.2	32.2	32.4	34.5	34.0	29.9	28.2	27.0	32.8	23.4	-650 bps	-942 bps
Total Expenditure	342.4	356.7	389.6	390.8	353.5	377.9	377.8	388.1	443.6	465.1	465.2	530.6	445.0	0.3	-16.1
% of Revenue	72.4	66.0	66.4	73.7	69.2	69.5	77.9	75.3	72.5	72.4	71.4	77.8	66.6	-589 bps	-1121 bps
EBITDA	130.7	183.7	197.5	139.5	157.5	166.2	107.3	127.1	168.4	177.6	186.0	151.3	223.2	32.6	47.5
EBITDA Margin (%)	27.6	34.0	33.6	26.3	30.8	30.5	22.1	24.7	27.5	27.6	28.6	22.2	33.4	589 bps	1121 bps
O ther Income	1.5	9.2	15.2	5.2	8.1	15.2	4.4	1.6	7.6	13.2	14.6	56.7	13.1	71.7	-76.9
Interest	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.8	1.8	4.9	1.6	3.6	1.6	-8.9	-55.0
Depreciation	13.4	14.6	15.0	16.6	17.2	17.5	18.7	18.8	22.8	23.3	23.6	26.0	28.0	23.0	7.6
PBT	118.7	178.3	197.5	128.0	148.3	163.8	93.0	109.2	151.5	162.6	175.4	178.4	206.7	36.5	15.9
Total Tax	23.9	46.4	50.1	33.5	42.5	38.5	26.1	20.3	36.8	45.2	67.6	46.7	58.9	60.0	26.2
Tax rate (%)	20.2	26.0	25.3	26.2	28.7	23.5	28.0	18.6	24.3	27.8	38.5	26.2	28.5	420 bps	233 bps
PAT	94.8	131.9	147.5	94.5	105.8	125.4	66.9	88.9	114.6	116.4	107.6	129.2	147.8	28.9	14.4
PAT Margin (%)	20.0	24.4	25.1	17.8	20.7	23.0	13.8	17.3	18.7	18.1	16.5	18.9	22.1	338 bps	317 bps

Source: ICICI Direct Research

Company Background

Established in 1973, Ajanta Pharma (Ajanta) is mainly into exports as well as domestic formulations. As of FY20, the exports: domestic formulation ratio was at 70:30. The company owns eight manufacturing facilities- four in Aurangabad (Maharashtra), one each in Dahej (Gujarat), Guwahati (Assam), the newly operationalized Pithampur (Madhya Pradesh) and Mauritius. Of these facilities, only one in Aurangabad is an API facility. The rest are all formulations. Consolidated revenues, EBITDA and PAT have grown at a CAGR of 10.3%, 4% and 3.2%, respectively, in FY16-20. Ajanta Pharma (Ajanta) had come out with a maiden IPO in March 2000. It raised ₹ 68 crore, which was earmarked for capacity expansion and debt repayment.

Domestic formulations constitute 30% of the total consolidated turnover (FY19). This segment has been further segregated into two sub-segments-1) branded formulations and 2) institutional business. Initially, the company was catering to the institutional business. The institutional sub-segment accounts for \sim 8% of domestic formulations and is mainly confined to government and institutional tenders. It is only in the last 10 years that the focus shifted to the branded formulations business, which now accounts for 92% of domestic formulations.

The company focuses on only a few so called specialty therapies – ophthalmology, dermatology and cardiology. Together, these therapies constitute ~92% of domestic branded formulations. Ajanta invested heavily in the technology and field force, especially in the first five years after the changed focus. The focus was also to offer novel delivery system. From ₹ 17 crore in FY05, formulations have grown to ₹ 705 crore in FY20. Till date, the company has launched 270+ products out of which 60% are first time launches. The current MR strength is 3000+. Overall, domestic branded formulations have grown at ~9% CAGR in FY16-20 to ₹ 705 crore. The company has only one product under the National List of Essential Medicines (NLEM) 2011 list.

Export formulations constitute 70% of total revenue (FY20). Exports are mainly confined to emerging markets and constitute branded generics. APL exports its products in ~31 emerging markets with a significant presence in Franco African countries and Philippines.


Asia accounts for ~38% of export formulations followed by Africa and US with 33% and 29% contribution to exports respectively. The company also participates in anti-malarial tenders in Africa. It operates through 710+ MRs in these emerging markets. APL owns a portfolio of more than 1350 registered brands in these markets encompassing major therapies such as anti-infectives, anti-malarials, ophthalmic, dermatology, cardiovascular, GI, etc. The company also has a marginal presence in Latin America. It has also forayed into regulated markets such as US where it has filed 57 ANDAs and received approvals for 38.

Result Update | Ajanta Pharmaceuticals





Source: ICICI Direct Research, Company






Exhibit 6: Domestic formulations

538.7

FY16

Source: ICICI Direct Research, Company

1000.0 900.0 800.0

700.0

600.0 500.0

400.0 300.0

200.0

100.0

0.0

CAGR 9.3%


614.0

FY17


629.0

FY18

Domestic Formulations



Source: ICICI Direct Research, Company



Source: ICICI Direct Research, Company

Source: ICICI Direct Research, Company

Exhibit 10: Export formulations (₹ crore) CAGR 10.4% 2183.1 2500.0 CAGR 11.1% 1790.3 1925.6 2000.0 1432.0 1319.0 1322.5 1500.0 1176.8 1000.0 500.0 0.0 FY16 FY17 FY18 FY19 FY20 FY21E FY22E Export formulations

Source: ICICI Direct Research, Company

ICICI Direct Research

CAGR 10.9%

FY20

769.0 788.2

⇒

690.0

FY19


(₹ crore)

FY21E FY22E


₹ 945.8

ICICI Securities | Retail Research





Source: ICICI Direct Research, Company



Source: ICICI Direct Research, Company

469.5

FY16

Exhibit 12: Asia revenues (₹ crore)

CAGR 9.5%

418.0

FY17

493.0

FY18

1000.0


800.0

600.0


400.0

200.0

0.0



Source: ICICI Direct Research, Company





Source: ICICI Direct Research, Company

Exhibit 17: Valuation

	Revenues	Growth	EPS	Growth	P/E	EV/EBITDA	RoE	RoCE
	(₹crore)	(%)	(₹)	(%)	(x)	(X)	(%)	(%)
FY19	2053	-3.7	43.5	-17.9	34.7	23.8	17.1	21.8
F Y 20	2588	26.1	53.4	21.6	28.6	19.2	18.1	24.7
FY21E	2768	7.0	60.2	13.7	25.1	15.8	17.7	23.4
FY 22E	3191	15.3	72.5	20.4	20.9	13.3	18.4	24.3

Source: ICICI Direct Research





CAGR 10.1%

674.0

FY20

528.0

FY19


Asia

726.2

FY21E

816.5

FY22E



Source: ICICI Direct Research; Bloomberg

Ran	k Investor Name	Filing Date	% 0/S	Position (m)	Change
1	Agrawal RaviP	31-Mar-20	14.6	12.74m	0.00m
2	Agrawal Yogesh M	31-Mar-20	14.5	12.64m	0.00m
3	Agrawal Rajesh M	31-Mar-20	14.5	12.64m	0.00m
4	Agrawal Ayush M	31-Mar-20	14.4	12.56m	0.00m
5	Gabs Investments Pvt	31-Mar-20	9.6	8.39m	0.00m
6	Mirae Asset Global I	31-May-20	3.3	2.89m	(0.07)m
7	Ganga Exports Pvt Lt	31-Mar-20	2.7	2.39m	0.00m
8	Uti Asset Management	31-May-20	2.7	2.36m	0.05m
9	Invesco India Asset	31-May-20	1.4	1.24m	(0.00)m
10	Vanguard Group	31-May-20	1.0	0.83m	(0.00)m

Source: ICICI Direct Research, Bloomberg

Exhibit 20: Shareh	olding Pattern				
(in %)	Jun-19	Sep-19	Dec-19	Mar-20	Jun-20
Promoter	70.5	70.5	70.5	70.5	70.5
0 thers	29.5	29.5	29.5	29.5	29.5

Source: ICICI Direct Research, Company

Financial Summary

(Year-end March)/ (₹cror	FY19	FY20	FY21E	FY22E
Total Operating Income	2,053.0	2,587.9	2,768.2	3,191.5
Growth (%)	-3.7	26.1	7.0	15.3
Raw Material Expenses	383.5	655.7	656.6	765.9
Gross Profit	1,669.5	1,932.2	2,111.5	2,425.5
Gross Profit Margins (%)	81.3	74.7	76.3	76.0
E mployee E xpenses	430.7	485.6	534.4	590.4
O ther E xpenditure	683.1	763.2	756.3	877.6
Total Operating Expenditu	1,497.3	1,904.5	1,947.3	2,234.0
EBITDA	555.8	683.3	820.9	957.4
Growth (%)	-15.6	23.0	20.1	16.6
Interest	1.2	11.9	6.5	6.5
Depreciation	72.1	95.7	112.1	118.6
O ther Income	29.4	92.2	29.9	44.7
PBT before Exceptional	511.9	667.9	732.2	877.0
Less: Exceptional Items	0.0	3.9	0.0	0.0
PBT after Exceptional Item	511.9	664.0	732.2	877.0
Total Tax	127.3	196.3	200.3	236.8
PAT before MI	384.6	467.7	531.9	640.2
PAT	384.6	467.7	531.9	640.2
Growth (%)	-17.9	21.6	13.7	20.4
EPS (Adjusted)	43.5	53.4	60.2	72.5

Exhibit 22: Cash Flow Sta			EVOLE	EVAAE
(Year-end March)/ (₹crore	FY19	FY20	FY21E	FY22E
Profit/(Loss) after taxation	396.0	509.1	531.9	640.2
Add: Depreciation & Amorti	72.1	95.7	112.1	118.6
Net Increase in Current Ass	-71.7	-316.4	-89.7	-297.2
Net Increase in Current Liak	-18.6	193.2	-54.7	50.5
0 thers	-3.0	-24.9	6.5	6.5
CF from Operating activit	374.8	456.8	506.1	518.6
(Purchase)/Sale of Fixed A	-342.3	-229.0	-220.0	-125.0
Investments	123.2	-1.7	-125.0	-200.0
0 thers	-157.6	7.3	1.0	1.1
CF from Investing activiti	-376.7	-223.4	-344.0	-323.9
(inc)/Dec in Loan	34.2	9.7	0.0	0.0
Dividend & Dividend tax	78.8	-115.9	-132.7	-159.8
0 ther	-101.2	-22.4	-6.5	-6.5
CF from Financing activities	11.8	-128.6	-139.3	-166.3
Net Cash Flow	9.9	104.7	22.9	28.4
Cash and Cash Equivalent	90.6	100.5	205.3	228.1
Cash	100.5	205.3	228.1	256.6
Free Cash Flow	32.4	227.7	286.1	393.6

Source: ICICI Direct Research

(Year-end March)	FY19	FY20	FY21E	FY22E		
(rour one maron)						
Equity Capital	17.5	17.5	17.5	17.5		
Reserve and Surplus	2,227.7	2,581.3	2,980.5	3,461.0		
Total Shareholders funds	2,245.2	2,598.9	2,998.0	3,478.5		
Total Debt	34.0	43.6	43.6	43.6		
Deferred Tax Liability	58.9	81.2	82.8	84.4		
Long-Term Provisions	13.8	15.7	16.0	16.3		
O ther Non Current Liabilitie	0.0	16.1	16.4	16.8		
Source of Funds	2,351.9	2,755.4	3,156.8	3,639.6		
Gross Block - Fixed Asset	1,610.3	1,976.2	2,171.2	2,371.2		
Accumulated Depreciation	431.8	504.0	616.1	734.6		
Net Block	1,178.6	1,472.1	1,555.1	1,636.5		
Capital WIP	261.3	131.9	156.9	81.9		
Fixed Assets	1,439.8	1,604.0	1,711.9	1,718.4		
Investments	77.7	79.4	204.4	404.4		
O ther non-Current Assets	62.2	60.7	61.9	63.2		
Inventory	435.7	495.7	663.3	808.5		
Debtors	459.5	775.3	695.4	845.4		
O ther Current Assets	120.8	98.3	100.3	102.3		
Cash	100.5	205.3	228.1	256.6		
Total Current Assets	1,116.5	1,574.6	1,687.1	2,012.8		
Creditors	225.2	362.3	303.6	350.0		
Provisions	25.0	9.2	9.3	9.5		
O ther Current Liabilities	94.2	191.8	195.7	199.6		
Total Current Liabilities	344.3	563.3	508.6	559.1		
Net Current Assets	772.2	1,011.3	1,178.5	1,453.6		
Application of Funds	2,351.9	2,755.4	3,156.8	3,639.6		

(Year-end March)	FY19	FY20	FY21E	FY22E	
Per share data (₹)					
Reported EPS	43.5	52.9	60.2	72.	
Cash EPS	32.7	40.2	45.2	54.4	
BV per share	254.1	294.2	339.3	393.	
Cash per Share	11.4	23.2	25.8	29.	
Dividend per share	10.9	13.2	15.0	18.	
Operating Ratios (%)					
Gross Profit Margins	81.3	74.7	76.3	76.	
EBITDA margins	27.1	26.4	29.7	30.	
PAT Margins	18.7	18.2	19.2	20.	
Cash Conversion Cycle	119.1	128.2	139.1	149.	
Asset Turnover	1.3	1.3	1.3	1.	
EBITDA conversion Rate	67.4	66.8	61.7	54.	
Return Ratios (%)					
RoE	17.1	18.1	17.7	18.	
RoCE	21.8	24.7	23.4	24.	
RoIC	25.1	25.0	27.5	28.	
Valuation Ratios (x)					
P/E	34.7	28.6	25.1	20.	
EV / EBITDA	23.8	19.2	15.8	13.	
EV / Net Sales	6.4	5.1	4.7	4.	
Market Cap / Sales	6.5	5.2	4.8	4.	
Price to Book Value	5.9	5.1	4.5	3.	
Solvency Ratios					
Debt / EBITDA	0.1	0.1	0.1	0.	
Debt / Equity	0.0	0.0	0.0	0.	
Current Ratio	3.0	2.4	2.9	3.	

Source: ICICI Direct Research

ICICI Direct Research

Exhibit 25: IC	ICI Direc	t cov	'erage	Univ	erse (F	lealthcare)													(₹ crore)		
Company	l-Direct	CMP			M Cap	EPS (ð			PE(x)				RoCE (%)					RoE (%)			
	Code	(₹)	(₹)							FY19											
Ajanta Pharma	AJAPHA	1512	1,810	Buy	13194	43.5	53.4	60.2	72.5	34.7	28.3	25.1	20.9	21.8	24.7	23.4	24.3	17.1	18.1	17.7	18.
Alembic Pharm	LEMPHA	1006	1,140	Buy	18956	31.4	46.3	52.6	51.9	32.0	21.7	19.1	19.4	19.6	21.0	21.9	20.1	21.8	27.1	24.1	19.
Apollo Hospital	APOHOS	1690	1,490	Buy	23514	17.0	23.3	37.3	68.0	99.6	72.4	45.4	24.8	8.8	10.4	11.2	14.6	7.1	9.7	12.8	19.
Aurobindo Pha	AURPHA	826	920	Buy	48390	41.9	48.8	57.8	63.0	19.7	16.9	14.3	13.1	15.9	17.2	19.1	19.1	17.7	17.0	17.0	15.
Biocon	B 10 C 0 N	400	490	Buy	48018	6.2	5.8	11.5	21.0	64.5	68.8	34.8	19.1	10.9	10.2	16.1	23.3	12.2	10.4	17.4	24.
Cadila Healthc;	CADHEA	365	420	Buy	37372	18.1	14.0	16.8	20.5	20.2	26.1	21.7	17.8	13.0	11.0	12.3	13.8	17.8	13.8	14.7	15.
Cipla	CIPLA	694	670	Buy	55958	18.6	19.2	23.0	30.2	37.3	36.1	30.1	23.0	10.9	12.0	13.0	15.4	10.0	9.8	10.8	12.
Divi's Lab	DIVLAB	2521	2,355	Hold	66925	51.0	51.9	60.7	73.6	49.5	48.6	41.5	34.3	25.5	23.9	23.8	24.0	19.4	18.8	18.7	19.
Dr Reddy's Lab	DRREDD	4300	5,000	Buy	71476	114.7	121.9	161.3	200.0	37.5	35.3	26.7	21.5	10.7	9.6	18.4	19.7	13.6	13.0	15.0	16.
Glenmark Phar	GLEPHA	447	510	Hold	12613	26.9	26.4	25.0	36.6	16.6	16.9	17.9	12.2	15.3	12.7	11.4	14.1	13.5	12.2	10.5	13.
Hikal	HIKCHE	153	165	Buy	1883	8.4	8.1	10.8	13.8	18.3	18.9	14.2	11.1	14.3	13.0	14.2	15.7	13.6	12.2	14.2	15.
lpca Laboratori	IPCLAB	1818	1,900	Buy	22967	35.1	47.8	61.7	76.8	51.9	38.0	29.5	23.7	15.0	17.4	19.4	20.2	14.2	16.6	17.8	18.
Jubilant Life	JUBLIF	788	550	Buy	12547	54.9	59.9	69.8	89.8	14.4	13.2	11.3	8.8	14.3	14.6	17.2	19.7	17.8	16.6	16.4	17.
Lupin	LUPIN	880	930	Hold	39854	16.5	-12.7	25.3	38.9	53.2	-69.3	34.8	22.6	9.4	10.6	10.7	14.6	5.4	-4.6	8.5	11.
Narayana Hrud	NARHRU	287	340	Buy	5863	2.9	6.4	-3.1	9.6	98.8	45.2	-93.4	29.9	7.7	11.0	0.0	14.2	5.5	11.4	-5.8	15.
Natco Pharma	NATPHA	723	740	Buy	13169	35.4	25.3	23.9	22.4	20.4	28.6	30.2	32.3	21.3	14.0	12.9	11.3	18.5	12.2	10.7	9.
Sun Pharma	SUNPHA	500	540	Buy	120000	15.9	16.8	15.5	24.1	31.6	29.8	32.3	20.8	10.3	10.0	8.9	12.3	9.2	8.9	7.7	10.
Syngene Int.	SYNINT	470	485	Buy	18812	8.3	10.3	9.2	12.8	56.9	45.7	45.3	32.7	14.8	14.5	13.1	16.4	16.8	15.7	14.5	16.
Torrent Pharma	TORPHA	2437	2,865	Buy	41239	48.9	60.6	72.2	95.5	49.8	40.2	33.8	25.5	14.2	15.4	18.6	21.8	17.5	21.2	21.3	23.
Shalby	SHALIM	77	70	Hold	831	2.9	2.6	0.7	4.0	26.3	30.1	104.8	19.1	6.8	7.2	1.8	7.0	4.1	3.5	1.0	5.
Aster DM	ASTDM	133	160	Buy	6619	6.7	5.5	-1.4	9.6	19.9	23.9	-92.0	13.8	8.3	7.5	2.6	9.7	10.4	8.5	-2.2	13.
Indoco Remedi	INDREM	214	260	Buv	1969	-0.3	2.6	7.4	14.3	-678.9	81.7	28.7	14.9	1.0	5.1	10.0	16.5	-0.4	3.5	9.3	15.

Source: ICICI Direct Research, Bloomberg

pankaj.pandey@icicisecurities.com

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorises them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%; Hold: -5% to 15%; Reduce: -5% to -15%; Sell: <-15%



Pankaj Pandey

Head – Research

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

ANALYST CERTIFICATION

We /l, Siddhant Khandekar, Inter CA, Mitesh Shah, CFA, Sudarshan Agarwal, PGDM (Finance), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risk associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.